AML: New Drugs but New Challenges.

Clinical Lymphoma, Myeloma & Leukemia
Alan Burnett, Richard M Stone

Abstract

Despite the approval of 8 new drugs for acute myeloid leukemia (AML) since 2017, the disease remains challenging, given the significant toxicity associated with available treatments and relatively low cure rates, especially in older adults. Although advantageous for patients, self-congratulatory rejoicing about the new agents would be extremely premature. Questions abound about the need for a specific versus less specific FLT3 inhibitor (eg, midostautin) in the upfront setting and whether a single agent (gilteritnib), albeit better than chemotherapy, is sufficient for relapsed disease. Is the new liposomal formulation of daunorubicin/cytarabine better than '3 + 7' only in secondary AML? Should only those newly diagnosed patients with core binding factor AML routinely receive gemtuzumab ozogamicin? The isocitrate dehydrogenase inhibitors were approved based on non-randomized data; thus, one wonders whether single-agent isocitrate dehydrogenase inhibitor therapy is appropriate for relapsed patients. Glasdegib, an orally available hedgehog inhibitor, is approved in conjunction with low-dose cytarabine in unfit patients but is rarely used in favor of a combination of hypomethylating agents or low-dose cytarabine with venetoclax, wh...Continue Reading

Citations

Feb 14, 2021·Journal of Translational Medicine·Caixia HanLi Yu
Dec 29, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettRuth Spearing
Jan 13, 2021·Blood Cancer Journal·Vikram J PremkumarPrashant Kapoor
Jul 20, 2021·Biomedical Materials·Pavol ŠtefíkPeter Šiffalovič

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Best Practice & Research. Clinical Haematology
Veronica A GuerraMarina Y Konopleva
British Journal of Clinical Pharmacology
Selin Kucukyurt, Ahmet Emre Eskazan
© 2021 Meta ULC. All rights reserved